title: Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
abstract: BACKGROUND
  Clinical trials have shown that the combination of pegylated interferon/ribavirin induces a sustained virological response in 54-63% of patients with chronic hepatitis C virus infection, but its effectiveness in day-to-day clinical practice is less clear.
  
  
  OBJECTIVE
  To verify if the efficacy of pegylated interferon/ribavirin combination in 'real world' patients is comparable to that observed in trials. Methods The medical records of 397 consecutive naïve patients with chronic hepatitis C virus infection treated with pegylated interferon/ribavirin combination in nontertiary hospital settings were reviewed in order to assess the response to anti-viral treatment.
  
  
  RESULTS
  The sustained virological response rate achieved in this population was similar to that recorded in registration trials (total population: 64%; genotype 1: 46%; genotypes 2-3: 84%). Also, the premature discontinuation rate (15%) was similar to that observed in registration trials, but there were fewer dose reductions in one or both medications (26%). We confirmed the association between adherence and sustained virological response among the patients infected with hepatitis C virus genotype 1 who were treated for > or =80% of the planned duration of treatment.
  
  
  CONCLUSIONS
  The effectiveness of pegylated interferon/ribavirin therapy and factors predicting an sustained virological response in everyday clinical practice mirror those reported in randomized-controlled studies.
authors.affiliation: Unità Organizzativa Alcoldipendenze, ASL Provincia di Milano 1, Abbiategrasso, Milan, Italy. noaabbiategrasso@libero.it
authors.forename: G
authors.initials: G
authors.lastname: Borroni
authors.forename: M
authors.initials: M
authors.lastname: Andreoletti
authors.forename: M A
authors.initials: MA
authors.lastname: Casiraghi
authors.forename: R
authors.initials: R
authors.lastname: Ceriani
authors.forename: P
authors.initials: P
authors.lastname: Guerzoni
authors.forename: B
authors.initials: B
authors.lastname: Omazzi
authors.forename: N
authors.initials: N
authors.lastname: Terreni
authors.forename: F
authors.initials: F
authors.lastname: Salerno
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004812:Epidemiologic Methods; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a